<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072668</url>
  </required_header>
  <id_info>
    <org_study_id>12-2607</org_study_id>
    <secondary_id>U01HL117659-01</secondary_id>
    <nct_id>NCT02072668</nct_id>
  </id_info>
  <brief_title>The Effect of Rivaroxaban in Sickle Cell Disease</brief_title>
  <official_title>The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary study hypothesis is that inhibition of factor Xa with rivaroxaban will reduce
      inflammation, coagulation and endothelial cell activation, and improve microvascular blood
      flow in patients with sickle cell disease (SCD) during the non-crisis, steady state. To test
      this hypothesis, this study will evaluate the effects of rivaroxaban on:

        -  plasma markers of inflammation;

        -  plasma markers of endothelial activation;

        -  plasma markers of thrombin generation; and

        -  microvascular blood flow assessed using laser Doppler velocimetry (LDV) of
           post-occlusive reactive hyperemia (PORH).

      In a cross-over design, subjects will receive rivaroxaban 20 mg/day and placebo for 4 weeks
      each, separated by a 2-week washout phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a Screening Phase, two Treatment Phases, a Wash-Out Phase, and a
      Follow-up Phase. The Screening Phase will occur within 28 days of randomization and will
      include informed consent, a physical examination, and complete medical history to include
      determination of sickle cell genotype and current medications. Clinical laboratory tests to
      be performed include: a Complete Blood Count (CBC) with differential and reticulocyte count;
      Prothrombin time(PT) / activated partial thromboplastin time (aPTT); and serum chemistries
      (BUN, creatinine, total and direct bilirubin, alanine aminotransferase (ALT), aspartate
      aminotransferase (AST), alkaline phosphatase, and LDH). A chest x-ray and MRI/MRA of the
      brain will also be done at Screening to rule out underlying disease.

      If the patient is found through the screening process to be eligible, the 1st Treatment Phase
      begins. Baseline safety assessments and measurement of biomarkers are completed, then the
      subject is randomized to receive rivaroxaban or placebo. After 4 weeks of treatment, there is
      a 2-Week Wash-Out Phase. After the Wash-Out Phase, another set of baseline studies are
      performed and the 2nd Treatment Phase begins. For this Phase of the study, the subject
      &quot;crosses over&quot; to receive whatever treatment - rivaroxaban or placebo - that they did not
      receive in the 1st Treatment Phase. After taking the assigned study drug for 4 weeks, the 2nd
      Treatment Phase ends. The subject returns 2 weeks after the last dose of study treatment for
      the Follow-Up Phase, consisting of a single end-of-study visit during which safety
      assessments are repeated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">October 4, 2018</completion_date>
  <primary_completion_date type="Actual">October 4, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 4 Weeks in Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Assay performed for soluble VCAM-1 using a commercially available enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to 4 Weeks in Interleukin-6 (IL-6)</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Assay performed for IL-6 using a commercially available enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in the Plasma Marker of Inflammation IL-2</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Interleukin-2 (IL-2) was measured using Luminex MAP technology at the UNC core facility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in the Plasma Marker of Inflammation IL-8</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Interleukin-8 (IL-8) was measured using Luminex MAP technology at the UNC core facility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Plasma Marker of Inflammation hsCRP</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>high sensitivity C-reactive protein (hsCRP) was measured using Luminex MAP technology at the UNC core facility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Plasma Marker of Inflammation MPO</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>myeloperoxidase (MPO) was measured using Luminex MAP technology at the UNC core facility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Plasma Marker of Inflammation TNF-a</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>tumor necrosis factor alpha (TNF-a) was measured using Luminex MAP technology at the UNC core facility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Plasma Marker of Inflammation sPLA2</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>secretory phospholipase A2 (sPLA2) was measured using Luminex MAP technology at the UNC core facility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Marker of Endothelial Cell (EC) Activation sICAM</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>levels of soluble intracellular adhesion molecule (sICAM) were measured using a commercially available ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in TH1</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: time to half before hyperemia (TH1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in TM</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: time to max (TM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in AH</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: hyperemia area (AH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ratio From Baseline to Week 4 in AH/AO</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variables measured: hyperemia area (AH) and occlusion area (AO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in PF</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: peak flow (PF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in RF</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: rest flow (RF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in TAT</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Assay for thrombin antithrombin (TAT) complexes performed using commercially available enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in D-Dimer</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Assay for D--dimer is performed using commercially available enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <condition>Sickle Cell-Beta0-Thalassemia</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban for 4 wks, Placebo for 4 wks</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for 4 wks, rivaroxaban for 4 wks</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <description>Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.</description>
    <arm_group_label>Placebo for 4 wks, rivaroxaban for 4 wks</arm_group_label>
    <arm_group_label>Rivaroxaban for 4 wks, Placebo for 4 wks</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.</description>
    <arm_group_label>Placebo for 4 wks, rivaroxaban for 4 wks</arm_group_label>
    <arm_group_label>Rivaroxaban for 4 wks, Placebo for 4 wks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years of age; sickle cell anemia (HbSS) or sickle-beta0 (HbSβ0) thalassemia;

          -  serum creatinine ≤ 1.0 mg/dL men) or 1.2 mg/dL (women);

          -  ALT &lt;/= 2 times upper limits of normal;

          -  platelet count ≥ 50,000 cu/mm;

          -  normal baseline PT/international normalized ratio (INR) and aPTT;

          -  be in the non-crisis, &quot;steady state&quot; with no severe pain episodes during the preceding
             4 weeks;

          -  ability to understand the requirements of the study and be willing to give informed
             consent;

          -  women of childbearing age must be practicing an adequate method of contraception;

          -  and if on hydroxyurea, be on a stable dose for at least 3 months prior to enrollment.

        Exclusion Criteria:

          -  hypersensitivity to any component of rivaroxaban;

          -  history of major GI bleeding or bleeding diathesis;

          -  baseline Hb &lt; 5.5 gm/dL;

          -  history of clinically overt stroke;

          -  brain magnetic resonance imaging with angiography (MRI/MRA) scan with evidence of Moya
             Moya;

          -  pregnant or breastfeeding;

          -  active liver disease or ALT &gt; 3 times upper limit of normal;

          -  on chronic anticoagulant, non-steroidal anti-inflammatory (NSAID) or statin therapy;

          -  history of metastatic cancer;

          -  current alcohol abuse;

          -  on a chronic transfusion program or any blood transfusion in the 3 months prior to
             enrollment;

          -  ingested any investigational drugs within the past 4 weeks;

          -  use of CYP3A4/P-glycoprotein inducers such as carbamazepine, phenytoin, rifampin, and
             St John's wort;

          -  use of CYP3A4/P- glycoprotein inhibitors such as ketoconazole, indinavir/ritonavir,
             itraconazole, lopinavir/ritonavir, ritonavir, and conivaptan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth I Ataga, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nigel Key, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <results_first_submitted>March 18, 2020</results_first_submitted>
  <results_first_submitted_qc>April 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2020</results_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sickle cell anemia</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>rivaroxaban</keyword>
  <keyword>direct Xa inhibition</keyword>
  <keyword>coagulation</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02072668/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>15 subjects signed informed consent and were successfully screened. One subject withdrew during Baseline and prior to the first intervention and data from this individual are included in the baseline characteristics. One subject entered the second intervention period but was lost to follow up before receiving the intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rivaroxaban, Then Placebo</title>
          <description>Participants first received Rivaroxaban 20 mg tablet once daily for 4 weeks. After a washout period of 2 weeks, they then received placebo (matching Rivaroxaban 20 mg tablet) once daily for 4 weeks.
Rivaroxaban: 20 mg tablet by mouth daily for 4 weeks Placebo: Matching placebo tablet by mouth daily for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Rivaroxaban</title>
          <description>Participants first received placebo (matching Rivaroxaban 20 mg tablet) once daily for 4 weeks. After a washout period of 2 weeks, they then received Rivaroxaban 20 mg tablet once daily for 4 weeks.
Rivaroxaban: 20 mg tablet by mouth daily for 4 weeks Placebo: Matching placebo tablet by mouth daily for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who had a screening visit</population>
      <group_list>
        <group group_id="B1">
          <title>Study Participants</title>
          <description>Participants who had a screening visit</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.00" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.22" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Only measured on the participants who received study medication</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.40" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>White Blood Cell (WBC) count</title>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.49" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Genotype - Hemoglobin SS (HbSS)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet count</title>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="370.07" spread="169.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prothrombin Time (PT)</title>
          <description>A test that measures how quickly blood clots</description>
          <population>Only measured on the participants who received study medication</population>
          <units>sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.54" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Normalized Ratio (INR)</title>
          <description>The ratio of a patient's prothrombin time to a normal (control) sample</description>
          <population>Only measured on the participants who received study medication</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.13" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Partial Thromboplastin Time (PTT)</title>
          <description>Measures the time it takes for a blood clot to form</description>
          <population>Only measured on the participants who received study medication</population>
          <units>sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.16" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 4 Weeks in Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1)</title>
        <description>Assay performed for soluble VCAM-1 using a commercially available enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Data reported only for those participants who completed both interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4 Weeks in Soluble Vascular Cell Adhesion Molecule-1 (VCAM-1)</title>
          <description>Assay performed for soluble VCAM-1 using a commercially available enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Data reported only for those participants who completed both interventions.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="-115.5" upper_limit="197.2"/>
                    <measurement group_id="O2" value="10.7" lower_limit="-84.5" upper_limit="105.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6281</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 4 Weeks in Interleukin-6 (IL-6)</title>
        <description>Assay performed for IL-6 using a commercially available enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Data reported only for those participants who completed both interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 4 Weeks in Interleukin-6 (IL-6)</title>
          <description>Assay performed for IL-6 using a commercially available enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Data reported only for those participants who completed both interventions.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-4.47" upper_limit="2.28"/>
                    <measurement group_id="O2" value="-0.54" lower_limit="-1.69" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7973</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in the Plasma Marker of Inflammation IL-2</title>
        <description>Interleukin-2 (IL-2) was measured using Luminex MAP technology at the UNC core facility</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Data analyzed for the 13 participants completing both interventions but results for 6 participants in each group fell outside the standard curve and could not be extrapolated.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in the Plasma Marker of Inflammation IL-2</title>
          <description>Interleukin-2 (IL-2) was measured using Luminex MAP technology at the UNC core facility</description>
          <population>Data analyzed for the 13 participants completing both interventions but results for 6 participants in each group fell outside the standard curve and could not be extrapolated.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" lower_limit="-4.13" upper_limit="1.85"/>
                    <measurement group_id="O2" value="0.36" lower_limit="-3.48" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4442</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in the Plasma Marker of Inflammation IL-8</title>
        <description>Interleukin-8 (IL-8) was measured using Luminex MAP technology at the UNC core facility</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Data analyzed for the 13 participants completing both interventions but results for 4 participants in the rivaroxaban group and 5 participants in the placebo group fell outside the standard curve and could not be extrapolated.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in the Plasma Marker of Inflammation IL-8</title>
          <description>Interleukin-8 (IL-8) was measured using Luminex MAP technology at the UNC core facility</description>
          <population>Data analyzed for the 13 participants completing both interventions but results for 4 participants in the rivaroxaban group and 5 participants in the placebo group fell outside the standard curve and could not be extrapolated.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="-41.83" upper_limit="43.72"/>
                    <measurement group_id="O2" value="-4.08" lower_limit="-38.36" upper_limit="30.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2545</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Plasma Marker of Inflammation hsCRP</title>
        <description>high sensitivity C-reactive protein (hsCRP) was measured using Luminex MAP technology at the UNC core facility.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Biomarker evaluations were limited to IL-2 and IL-8 as those were thought more likely to reflect inflammation activation based on experience in recent studies.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Plasma Marker of Inflammation hsCRP</title>
          <description>high sensitivity C-reactive protein (hsCRP) was measured using Luminex MAP technology at the UNC core facility.</description>
          <population>Biomarker evaluations were limited to IL-2 and IL-8 as those were thought more likely to reflect inflammation activation based on experience in recent studies.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Plasma Marker of Inflammation MPO</title>
        <description>myeloperoxidase (MPO) was measured using Luminex MAP technology at the UNC core facility.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Biomarker evaluations were limited to IL-2 and IL-8 as those were thought more likely to reflect inflammation activation based on experience in recent studies.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Plasma Marker of Inflammation MPO</title>
          <description>myeloperoxidase (MPO) was measured using Luminex MAP technology at the UNC core facility.</description>
          <population>Biomarker evaluations were limited to IL-2 and IL-8 as those were thought more likely to reflect inflammation activation based on experience in recent studies.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Plasma Marker of Inflammation TNF-a</title>
        <description>tumor necrosis factor alpha (TNF-a) was measured using Luminex MAP technology at the UNC core facility.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Biomarker evaluations were limited to IL-2 and IL-8 as those were thought more likely to reflect inflammation activation based on experience in recent studies.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Plasma Marker of Inflammation TNF-a</title>
          <description>tumor necrosis factor alpha (TNF-a) was measured using Luminex MAP technology at the UNC core facility.</description>
          <population>Biomarker evaluations were limited to IL-2 and IL-8 as those were thought more likely to reflect inflammation activation based on experience in recent studies.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Plasma Marker of Inflammation sPLA2</title>
        <description>secretory phospholipase A2 (sPLA2) was measured using Luminex MAP technology at the UNC core facility</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Biomarker evaluations were limited to IL-2 and IL-8 as those were thought more likely to reflect inflammation activation based on experience in recent studies.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Plasma Marker of Inflammation sPLA2</title>
          <description>secretory phospholipase A2 (sPLA2) was measured using Luminex MAP technology at the UNC core facility</description>
          <population>Biomarker evaluations were limited to IL-2 and IL-8 as those were thought more likely to reflect inflammation activation based on experience in recent studies.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Marker of Endothelial Cell (EC) Activation sICAM</title>
        <description>levels of soluble intracellular adhesion molecule (sICAM) were measured using a commercially available ELISA</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Biomarker evaluations were limited to VCAM-1 and IL-6 as those were thought more likely to reflect endothelial cell activation based on experience in recent studies.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban, Then Placebo</title>
            <description>Participants first received Rivaroxaban 20 mg tablet once daily for 4 weeks. After a washout period of 2 weeks, they then received placebo (matching Rivaroxaban 20 mg tablet) once daily for 4 weeks.
Rivaroxaban: 20 mg tablet by mouth daily for 4 weeks Placebo: Matching placebo tablet by mouth daily for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Then Rivaroxaban</title>
            <description>Participants first received placebo (matching Rivaroxaban 20 mg tablet) once daily for 4 weeks. After a washout period of 2 weeks, they then received Rivaroxaban 20 mg tablet once daily for 4 weeks.
Rivaroxaban: 20 mg tablet by mouth daily for 4 weeks Placebo: Matching placebo tablet by mouth daily for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Marker of Endothelial Cell (EC) Activation sICAM</title>
          <description>levels of soluble intracellular adhesion molecule (sICAM) were measured using a commercially available ELISA</description>
          <population>Biomarker evaluations were limited to VCAM-1 and IL-6 as those were thought more likely to reflect endothelial cell activation based on experience in recent studies.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in TH1</title>
        <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: time to half before hyperemia (TH1)</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>All participants randomized to each treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in TH1</title>
          <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: time to half before hyperemia (TH1)</description>
          <population>All participants randomized to each treatment were analyzed.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="-0.79" upper_limit="2.47"/>
                    <measurement group_id="O2" value="-0.51" lower_limit="-2.72" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4374</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in TM</title>
        <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: time to max (TM)</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>All participants randomized to each treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in TM</title>
          <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: time to max (TM)</description>
          <population>All participants randomized to each treatment were analyzed.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" lower_limit="-5.71" upper_limit="3.77"/>
                    <measurement group_id="O2" value="-2.01" lower_limit="-6.82" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3470</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in AH</title>
        <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: hyperemia area (AH)</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>All participants randomized to each treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in AH</title>
          <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: hyperemia area (AH)</description>
          <population>All participants randomized to each treatment were analyzed.</population>
          <units>perfusion units*seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="-373" upper_limit="628"/>
                    <measurement group_id="O2" value="-1189" lower_limit="-2597" upper_limit="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0755</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ratio From Baseline to Week 4 in AH/AO</title>
        <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variables measured: hyperemia area (AH) and occlusion area (AO)</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>All participants randomized to each treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ratio From Baseline to Week 4 in AH/AO</title>
          <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variables measured: hyperemia area (AH) and occlusion area (AO)</description>
          <population>All participants randomized to each treatment were analyzed.</population>
          <units>ratio of AH to AO</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-0.46" upper_limit="0.57"/>
                    <measurement group_id="O2" value="-0.81" lower_limit="-2.05" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in PF</title>
        <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: peak flow (PF)</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>All participants randomized to each treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in PF</title>
          <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: peak flow (PF)</description>
          <population>All participants randomized to each treatment were analyzed.</population>
          <units>perfusion units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" lower_limit="-9.08" upper_limit="15.36"/>
                    <measurement group_id="O2" value="-12.62" lower_limit="-26.63" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0708</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in RF</title>
        <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: rest flow (RF)</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>All participants randomized to each treatment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in RF</title>
          <description>Microvascular blood flow was measured using laser doppler velocimetry (LDV) assessments of post-occlusive reactive hyperemia (PORH). This was accomplished using the Perimed PF5001 Velocitometer (Stockholm, Sweden). Variable measured: rest flow (RF)</description>
          <population>All participants randomized to each treatment were analyzed.</population>
          <units>perfusion units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="-1.47" upper_limit="2.05"/>
                    <measurement group_id="O2" value="-0.62" lower_limit="-2.96" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4501</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in TAT</title>
        <description>Assay for thrombin antithrombin (TAT) complexes performed using commercially available enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Data reported only for those participants who completed both interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in TAT</title>
          <description>Assay for thrombin antithrombin (TAT) complexes performed using commercially available enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Data reported only for those participants who completed both interventions.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.44" lower_limit="-69.4" upper_limit="0.53"/>
                    <measurement group_id="O2" value="0.35" lower_limit="-3.77" upper_limit="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0767</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in D-Dimer</title>
        <description>Assay for D--dimer is performed using commercially available enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Data reported only for those participants who completed both interventions.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in D-Dimer</title>
          <description>Assay for D--dimer is performed using commercially available enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Data reported only for those participants who completed both interventions.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-471" lower_limit="-1654" upper_limit="712"/>
                    <measurement group_id="O2" value="-1035" lower_limit="-3880" upper_limit="1810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7250</p_value>
            <method>Student t-test followed by ANOVA</method>
            <method_desc>Student t-test subsequently followed by crossover ANOVA model testing carry-over effect and treatment effect</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collected from date of informed consent to end of study visit, approximately 3 months</time_frame>
      <desc>The safety analysis population includes all participants exposed to any study intervention evaluated in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rivaroxaban</title>
          <description>Participants who received Rivaroxaban 20 mg tablet in either the first or the second half of the study</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants who received placebo tablet (matching Rivaroxaban 20 mg) in either the first or the second half of the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>painful crisis with bacteremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea, nausea and vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>elevate liver enzymes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>right flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>pain in lower extremities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>pelvic pressure with urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough, fever, body aches, congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ankle laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>tick bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>tinea versicolor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>pain crisis treated at home</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kenneth Ataga</name_or_title>
      <organization>University of Tennessee Center for the Heath Sciences</organization>
      <phone>901.448.3181</phone>
      <email>kataga@uthsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

